Tiziana Life Sciences announces discovery of new immune biomarkers

Tiziana Life Sciences (TLSA) announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab. The company believes these findings contribute to its understanding of the immune mechanisms underlying the effects of nasal foralumab. The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in its ongoing expanded access program. Key findings include modulation of: FoxP3 T regulatory cells; CD4+ and CD8+ central memory T cells; CD14+ and CD14- monocytes and Naive B cells.These pathways are known to be associated with antigen presentation, interferon responses, and other regulatory immune mechanisms. In this study, single-cell RNA sequencing of peripheral blood samples taken before and at three and six months after drug administration has revealed relevant gene expression changes associated with nasal foralumab, which has been associated with a reduction in microglial brain inflammation, as measured by advanced microglial PET scans in these same patients.